Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization

This trial is a randomized, double-blind, parallel-group, multicenter study to be conducted in the United States. The purpose of the study is to evaluate the rate of exacerbations of chronic obstructive pulmonary disease (COPD) following hospital discharge for an acute exacerbation of COPD, in patients receiving either fluticasone propionate/salmeterol combination product 250/50mcg BID or salmeterol 50mcg BID via DISKUS™ over 29 weeks. The study population will include patients hospitalized for an acute exacerbation of COPD. The target enrolment is 720 subjects at 80 study centers. The primary endpoint is the rate of exacerbation requiring hospitalization that occur more than 21 days post-discharge, emergency room visit or physician's office visit for an exacerbation of COPD requiring treatment with oral corticosteroids or oral corticosteroids and antibiotics. The secondary endpoint is the rate of COPD exacerbation requiring treatment with oral corticosteroids, antibiotics, and/or hospitalization (alone and in combination). Related efficacy endpoints include, time to first exacerbation of COPD requiring treatment with oral corticosteroids, antibiotics, and/or hospitalization (alone and in combination), pre-dose AM FEV1, the probability of premature withdrawal of subject from the study, and supplemental albuterol use, change in biomarkers of inflammation, including, surfactant protein D (SP-D), clara cell secretory protein 16 (CC-16) and high sensitivity C-reactive protein (hs-CRP). Health outcome assessments include domain scores evaluation for fatigue, dyspnea, emotional function and mastery, measured with the Chronic Respiratory Disease Questionnaire self-administered standardized format (CRQ-SAS); and symptoms (congestion, cough, phlegm, mucus, chest discomfort, shortness of breath and sleep disturbance), assessed by the EXAcerbations of Chronic pulmonary disease Tool (EXACT). Albuterol will be supplied to study subjects for use as-needed throughout the study. Safety will be assessed by monitoring of adverse events.

Study Overview

• Status: Completed
• Conditions: Pulmonary Disease, Chronic Obstructive
• Intervention / Treatment: Drug: ADVAIR DISKUS 250/50 mg BID; Drug: SEREVENT 50 mcg BID

• Study Type: Interventional
• Enrollment (Actual): 639
• Phase: Phase 4

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, C1120AAC
    • GSK Investigational Site
  • Ciudad Autónoma de Buenos Aires, Argentina, C1426ABP
    • GSK Investigational Site
  • Corrientes, Argentina, W3410AVV
    • GSK Investigational Site
  • San Juan, Argentina, 5400
    • GSK Investigational Site
  • San Salvador de Jujuy, Argentina
    • GSK Investigational Site
  • Santa Fe, Argentina, 3000
    • GSK Investigational Site
  • Santa Fe, Argentina, 3016
    • GSK Investigational Site
  • Santa Fe, Argentina, S3000AZG
    • GSK Investigational Site
  • Tucumán, Argentina, T4000DGF
    • GSK Investigational Site
  • Buenos Aires
    • Bahía Blanca, Buenos Aires, Argentina, B8000AAK
      • GSK Investigational Site
    • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1431FWO
      • GSK Investigational Site
    • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1405BCH
      • GSK Investigational Site
    • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1425DQI
      • GSK Investigational Site
    • Florencio Varela, Buenos Aires, Argentina, 1888
      • GSK Investigational Site
    • Mar del Plata, Buenos Aires, Argentina, 7600
      • GSK Investigational Site
    • Nueve de Julio, Buenos Aires, Argentina, B6500BWQ
      • GSK Investigational Site
  • Chubut
    • Comodoro Rivadavia, Chubut, Argentina, U9000AKX
      • GSK Investigational Site
  • Entre Ríos
    • Concepcion del Uruguay, Entre Ríos, Argentina, 3260
      • GSK Investigational Site
  • Mendoza
    • Godoy Cruz, Mendoza, Argentina, MQ 5500
      • GSK Investigational Site
    • San Rafael, Mendoza, Argentina, M5602HWT
      • GSK Investigational Site
  • Río Negro
    • Cipolletti, Río Negro, Argentina, 8324
      • GSK Investigational Site
    • San Carlos de Bariloche, Río Negro, Argentina, R8401DKA
      • GSK Investigational Site
  • Santa Cruz
    • El Calafate, Santa Cruz, Argentina, Z9405CJM
      • GSK Investigational Site
• Norway
  • Bodø, Norway, 8005
    • GSK Investigational Site
  • Levanger, Norway, 7600
    • GSK Investigational Site
  • Stavanger, Norway, 4011
    • GSK Investigational Site
  • Trondheim, Norway, 7030
    • GSK Investigational Site
  • Tønsberg, Norway, 3116
    • GSK Investigational Site
  • Volda, Norway, 6100
    • GSK Investigational Site
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • GSK Investigational Site
    • Birmingham, Alabama, United States, 35233
      • GSK Investigational Site
    • Florence, Alabama, United States, 35630
      • GSK Investigational Site
    • Mobile, Alabama, United States, 36608
      • GSK Investigational Site
  • Alaska
    • Anchorage, Alaska, United States, 99508
      • GSK Investigational Site
  • Arizona
    • Glendale, Arizona, United States, 85306
      • GSK Investigational Site
    • Phoenix, Arizona, United States, 85023
      • GSK Investigational Site
    • Phoenix, Arizona, United States, 85012
      • GSK Investigational Site
    • Tucson, Arizona, United States, 85710
      • GSK Investigational Site
  • California
    • Fresno, California, United States, 93702
      • GSK Investigational Site
    • Loma Linda, California, United States, 92357
      • GSK Investigational Site
    • Long Beach, California, United States, 90822
      • GSK Investigational Site
    • Newport Beach, California, United States, 92663
      • GSK Investigational Site
    • Riverside, California, United States, 92506
      • GSK Investigational Site
    • San Diego, California, United States, 92117
      • GSK Investigational Site
    • Sepulveda, California, United States, 91343
      • GSK Investigational Site
    • Torrance, California, United States, 90505
      • GSK Investigational Site
  • Connecticut
    • Hartford, Connecticut, United States, 06105
      • GSK Investigational Site
  • District of Columbia
    • Washington, D.C., District of Columbia, United States, 20037
      • GSK Investigational Site
  • Florida
    • Bay Pines, Florida, United States, 33744
      • GSK Investigational Site
    • Brandon, Florida, United States, 33511
      • GSK Investigational Site
    • Clearwater, Florida, United States, 33756
      • GSK Investigational Site
    • Cocoa, Florida, United States, 32927
      • GSK Investigational Site
    • Fort Lauderdale, Florida, United States, 33316
      • GSK Investigational Site
    • Gainesville, Florida, United States, 32608
      • GSK Investigational Site
    • Kissimmee, Florida, United States, 34741
      • GSK Investigational Site
    • Orlando, Florida, United States, 32822
      • GSK Investigational Site
    • Winter Park, Florida, United States, 32789
      • GSK Investigational Site
    • Winter Park, Florida, United States, 32792
      • GSK Investigational Site
  • Georgia
    • Lawrenceville, Georgia, United States, 30046
      • GSK Investigational Site
  • Illinois
    • Belleville, Illinois, United States, 62220
      • GSK Investigational Site
  • Iowa
    • Council Bluffs, Iowa, United States, 51503
      • GSK Investigational Site
  • Kansas
    • Wichita, Kansas, United States, 67218
      • GSK Investigational Site
  • Maryland
    • Baltimore, Maryland, United States, 21224
      • GSK Investigational Site
    • Columbia, Maryland, United States, 21044
      • GSK Investigational Site
  • Michigan
    • Livonia, Michigan, United States, 48152
      • GSK Investigational Site
  • Minnesota
    • Fridley, Minnesota, United States, 55432
      • GSK Investigational Site
    • Minneapolis, Minnesota, United States, 55407
      • GSK Investigational Site
  • Missouri
    • Kansas City, Missouri, United States, 64128
      • GSK Investigational Site
    • Kansas City, Missouri, United States, 64108
      • GSK Investigational Site
    • Saint Louis, Missouri, United States, 63141
      • GSK Investigational Site
  • Nebraska
    • Lincoln, Nebraska, United States, 68506
      • GSK Investigational Site
    • Omaha, Nebraska, United States, 68198
      • GSK Investigational Site
  • New York
    • Buffalo, New York, United States, 14215-1199
      • GSK Investigational Site
    • North Syracuse, New York, United States, 13212
      • GSK Investigational Site
  • North Carolina
    • Charlotte, North Carolina, United States, 28207
      • GSK Investigational Site
    • Durham, North Carolina, United States, 27705
      • GSK Investigational Site
    • Elizabeth City, North Carolina, United States, 27909
      • GSK Investigational Site
    • Statesville, North Carolina, United States, 28625
      • GSK Investigational Site
    • Wilmington, North Carolina, United States, 28401
      • GSK Investigational Site
    • Winston-Salem, North Carolina, United States, 27103
      • GSK Investigational Site
  • Ohio
    • Canton, Ohio, United States, 44718
      • GSK Investigational Site
    • Cincinnati, Ohio, United States, 45220
      • GSK Investigational Site
    • Dayton, Ohio, United States, 45459
      • GSK Investigational Site
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • GSK Investigational Site
  • Oregon
    • Portland, Oregon, United States, 97220
      • GSK Investigational Site
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19140
      • GSK Investigational Site
    • Pittsburgh, Pennsylvania, United States, 15025
      • GSK Investigational Site
  • South Carolina
    • Charleston, South Carolina, United States, 29406-7108
      • GSK Investigational Site
    • Easley, South Carolina, United States, 29640
      • GSK Investigational Site
    • Fort Mill, South Carolina, United States, 29707
      • GSK Investigational Site
    • Gaffney, South Carolina, United States, 29340
      • GSK Investigational Site
    • Greenville, South Carolina, United States, 29615
      • GSK Investigational Site
    • Seneca, South Carolina, United States, 29678
      • GSK Investigational Site
    • Spartanburg, South Carolina, United States, 29303
      • GSK Investigational Site
    • Union, South Carolina, United States, 29379
      • GSK Investigational Site
  • Texas
    • Corsicana, Texas, United States, 75110
      • GSK Investigational Site
    • Dallas, Texas, United States, 75231
      • GSK Investigational Site
    • Dallas, Texas, United States, 75216
      • GSK Investigational Site
    • Houston, Texas, United States, 77030
      • GSK Investigational Site
  • Virginia
    • Abingdon, Virginia, United States, 24210
      • GSK Investigational Site
    • Fairfax, Virginia, United States, 22030
      • GSK Investigational Site
    • Richmond, Virginia, United States, 23225
      • GSK Investigational Site
  • Washington
    • Spokane, Washington, United States, 99204
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Subjects eligible for enrolment in this study must meet all of the following criteria:

• Male or female of at least 40 years of age at screening.

To be eligible for entry into the study, females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control starting on the day of visit 1, throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days), as defined by any one of the following:

• Abstinence Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse
• Oral contraceptive (either combined estrogen/progestin or progestin only)
• Injectable progestogen
• Implants of levonorgestrel or etonogestrel
• Percutaneous contraceptive patches
• Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year,
• Male partner who is sterile (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study and is the sole sexual partner for that female subject, or
• Double-barrier method; condom or occlusive cap (diaphragm or cervical /vault caps) plus spermicide.
• Current or former smokers with a >10 pack-year cigarette smoking history [number of pack years = (number of cigarettes per day / 20) X number of years smoked (e.g., 10 pack-years is equal to 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years]. Former smokers are defined as those who have quit smoking for at least 3 months prior to the screening visit.
• Any of the following populations:
• Patients hospitalized for a duration not exceeding 10 days due to an acute exacerbation of COPD, and who must be randomized within 10 days post-discharge.
• Patients with COPD who were treated and held for observation in the emergency department (i.e. emergency room, ER) for at least 24 hours due to an acute exacerbation of COPD, and who must be randomized within 10 days post-discharge.
• Patients who received oral corticosteroids or oral corticosteroids and antibiotics for treatment of an exacerbation of COPD during a physician's office visit and who must be randomized within 10 days of the visit, and who have been hospitalized within the previous six months due to an acute exacerbation of COPD.
• Clinical diagnosis of COPD (for at least 6 months). The following definition of COPD from the American Thoracic Society (ATS) will be used: COPD is a disease state characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema; the airflow obstruction is generally progressive, may be accompanied by airway hyper-reactivity, and may be partially reversible [American Thoracic Society, 1995].
• Documented evidence (within a year prior to Visit 1) in the medical chart of spirometry confirming the diagnosis of COPD and/or spirometry performed prior to randomization (Visit 2) that confirms pre-bronchodilator FEV1/FVC ratio less than or equal to 0.70 and pre-bronchodilator FEV1 <70% of predicted.
• Review and subject's completion of written informed consent: a subject-signed and dated written informed consent (form) must be obtained prior to any study procedure, and the subject must be willing to comply with all the requirements of the study protocol.
• Subject must be able to read, comprehend, and record information in English or Spanish.

Exclusion Criteria:

• Subjects meeting any of the following criteria must not be enrolled in the study:
• Diagnosis of pneumonia, congestive heart failure (CHF), or other complicating co-morbid condition while hospitalized within the last 6 months for an exacerbation of COPD.
• Historical or current evidence of clinically significant uncontrolled disease including, but not limited to, those listed below. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subjects at risk through study participation, or which would affect the safety analysis or other analyses if the disease/condition exacerbated during the study.
• A previous lung resection surgery (e.g. lobectomy, pneumonectomy, etc) within the year preceding Visit 1 (Screening)
• Asthma as primary diagnosis
• Lung cancer
• Cystic fibrosis, pulmonary fibrosis, active tuberculosis, or sarcoidosis
• Clinically significant cardiac arrhythmias
• Uncontrolled hypertension
• Unstable angina
• Current malignancy or a previous history of cancer in remission for < 5yrs (localized basal cell or squamous cell carcinoma of the skin that has been resected is not excluded)
• Uncontrolled diabetes mellitus
• Uncontrolled hyperthyroidism or hypothyroidism
• Immunologic compromise
• Cushing's or Addison's disease
• An abnormal 12-lead electrocardiogram (ECG) at Visit 1 (Screening) deemed to be clinically significant by the investigator.
• A chest X-ray or computed tomography (CT) scan performed in the 6 months preceding Visit 1 that revealed evidence of clinically significant abnormalities not believed to be due to the presence of COPD. If the subject does not have a record of a chest X-ray, one must be obtained and reviewed prior to randomization.
• Female patients with a positive urine pregnancy test at Visit 1.
• Any infirmity, physical disability, or geographic location that would limit compliance for scheduled visits.
• Any adverse reaction, immediate or delayed, hypersensitivity to any Beta-agonist, sympathomimetic drug, or corticosteroid including any components of the study drug formulations.
• Limited ability to provide a valid informed consent due to psychiatric disease, intellectual deficiency, poor motivation, current substance abuse (including illicit drugs and alcohol), or neurological disorders that might interfere with completion of study procedures or hearing problems that may impede effective communication.
• Study site staff (i.e. participating investigator, sub-investigator, study coordinator, employee of the participating investigator) or family members of site staffs.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: ADVAIR DISKUS 250/50 mcg BID; Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.	Drug: ADVAIR DISKUS 250/50 mg BID; Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.; Other Names: FSC 250/50 mcg
Active Comparator: Serevent 50 mcg BID; Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).	Drug: SEREVENT 50 mcg BID; Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).; Other Names: Salmeterol xinafoate 50 mcg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Par. With Chronic Obstructive Pulmonary Disease (COPD) EXs Requiring Hospitalization That Occurred >21 Days Post-discharge/Physician's Office Visit for a COPD EX Requiring Treatment With Oral Corticosteroids (OCSs) or OCSs and Antibiotics (ABs)	A COPD exacerbation (EX) was defined as the worsening of >=2 major symptoms (dyspnoea, sputum volume, sputum purulence [containing/discharging pus]) or the worsening of any 1 major symptom together with any 1 minor symptom (sore throat, cold [nasal discharge and/or nasal conjestion], fever without other cause, increased cough or wheeze) for at least 2 consecutive days. COPD EXs were identified by symptom review, and/or were based on investigator judgment (via phone contact or at a clinic visit). Hospitalization had to occur >21 days post-discharge/physician's office visit for a prior COPD EX.	From 21 days post-discharge (hospital or emergency room) or physician's office visit, up to 29 weeks
Number of Participants With the Indicated Number of EXs of COPD Requiring Hospitalization That Occurred More Than 21 Days Post-discharge or Physician's Office Visit for an EX of COPD Requiring Treatment With OCSs or OCSs and ABs	A COPD EX was defined as the worsening of >=2 major symptoms (dyspnoea, sputum volume, sputum purulence [containing/discharging pus]) or the worsening of any 1 major symptom together with any 1 minor symptom (sore throat, cold [nasal discharge and/or nasal conjestion], fever without other cause, increased cough or wheeze) for at least 2 consecutive days. COPD EXs were identified by symptom review, and/or were based on investigator judgment (via phone contact or at a clinic visit). Hospitalization had to occur more than 21 days post-discharge or physician's office visit for a prior COPD EX.	From 21 days post-discharge (hospital or emergency room) or physician's office visit, up to 29 weeks
Number of EXs of COPD Requiring Hospitalization That Occurred More Than 21 Days Post-discharge or Physician's Office Visit for an EX of COPD Requiring Treatment With OCSs or OCSs and ABs	A COPD EX was defined as the worsening of >=2 major symptoms (dyspnoea, sputum volume, sputum purulence [containing/discharging pus]) or the worsening of any 1 major symptom together with any 1 minor symptom (sore throat, cold [nasal discharge and/or nasal conjestion], fever without other cause, increased cough or wheeze) for at least 2 consecutive days. COPD EXs were identified by symptom review, and/or were based on investigator judgment (via phone contact or at a clinic visit). Hospitalization had to occur more than 21 days post-discharge or physician's office visit for a prior COPD EX.	From 21 days post-discharge (hospital or emergency room) or physician's office visit, up to 29 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With an EX of COPD Requiring Treatment With OCSs, Treatment With ABs, and/or Hospitalization	A COPD EX was defined as the worsening of >=2 major symptoms (dyspnoea, sputum volume, sputum purulence [containing/discharging pus]) or the worsening of any 1 major symptom together with any 1 minor symptom (sore throat, cold [nasal discharge and/or nasal conjestion], fever without other cause, increased cough or wheeze) for at least 2 consecutive days. COPD EXs were identified by symptom review, and/or were based on investigator judgment (via phone contact or at a clinic visit).	From Baseline up to Week 29, approximately
Number of EXs of COPD Requiring Treatment With OCSs, Treatment With ABs, and/or Hospitalization (Alone and in Combination)	A COPD EX was defined as the worsening of >=2 major symptoms (dyspnoea, sputum volume, sputum purulence [containing/discharging pus]) or the worsening of any 1 major symptom together with any 1 minor symptom (sore throat, cold [nasal discharge and/or nasal conjestion], fever without other cause, increased cough or wheeze) for at least 2 consecutive days. COPD EXs were identified by symptom review, and/or were based on investigator judgment (via phone contact or at a clinic visit).	From Baseline up to Week 29, approximately

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Ohar JA, Crater GD, Emmett A, Ferro TJ, Morris AN, Raphiou I, Sriram PS, Dransfield MT. Fluticasone propionate/salmeterol 250/50 mug versus salmeterol 50 mug after chronic obstructive pulmonary disease exacerbation. Respir Res. 2014 Sep 24;15(1):105. doi: 10.1186/s12931-014-0105-2.

Helpful Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Study record dates

Study Major Dates

• Study Start: April 30, 2010
• Primary Completion (Actual): April 1, 2012
• Study Completion (Actual): May 8, 2012

Study Registration Dates

• First Submitted: April 22, 2010
• First Submitted That Met QC Criteria: April 22, 2010
• First Posted (Estimate): April 26, 2010

Study Record Updates

• Last Update Posted (Actual): November 8, 2017
• Last Update Submitted That Met QC Criteria: October 9, 2017
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Keywords: Chronic Obstructive Pulmonary Disease (COPD); Hospitalization; Exacerbations of COPD
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Pulmonary Disease, Chronic Obstructive; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Adrenergic Agonists; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Sympathomimetics; Salmeterol Xinafoate; Fluticasone-Salmeterol Drug Combination
• Other Study ID Numbers: 113874

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

1. Clinical Study Report
   Information identifier: 113874
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
2. Informed Consent Form
   Information identifier: 113874
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
3. Annotated Case Report Form
   Information identifier: 113874
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
4. Study Protocol
   Information identifier: 113874
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
5. Statistical Analysis Plan
   Information identifier: 113874
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
6. Individual Participant Data Set
   Information identifier: 113874
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
7. Dataset Specification
   Information identifier: 113874
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register